Microbot Medical Takes Step Towards Human Clinical Trial in US
    Microbot Medical Takes Step Towards Human Clinical Trial in US
    PRISM Biotech

    February 08, 2024 - by Catie Corcoran

    Microbot Medical Takes Step Towards Human Clinical Trial in US

    08 February 2024

    New York, February 08, 2024 - PRISM MarketView - Surgical robotics company, Microbot Medical (Nasdaq: MBOT) has taken an important step closer to initiating a pivotal human clinical trial in the United States with the filing of an Investigational Device Exemption (IDE) application with the FDA. Microbot is the developer of the LIBERTY® Endovascular Robotic Surgical System.
    Microbot Medical Inc. - Prism MarketView

    Microbot Medical Inc. - Prism MarketView

    Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minim

    Read More

    Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US

    The Investigational Device Exemption (IDE) application follows the completion of multiple activities necessary to file this applicationBRAINTREE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the LIBERTY® Endovascular Robotic Surgical System, announced that it has filed an Investigational Device Exemption (IDE) application with the US Food and Drug Administration (FDA). The IDE application follows the completion of multiple preclinical activities per

    Read More

    Last month, the company announced the successful completion of its good laboratory practices (GLP) pivotal pre-clinical study using a porcine model. The study was conducted by three leading interventional radiologists that utilized the LIBERTY Endovascular Robotic Surgical System to perform a total of 96 robotic navigations. Microbot said the preclinical results would allow the company to continue its transition from R&D and pre-clinical phase into the clinical, regulatory and pre-commercial phase.

    Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met

    The results of the study will support the Company’s IDE submission to the FDA to commence its human clinical studyBRAINTREE, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model. As previously a

    Read More

    “This is an important milestone for the company, and it is another step forward in our journey to achieve FDA clearance for the LIBERTY® Endovascular Robotic Surgical System.”

    Harel Gadot, CEO, President and Chairman of Microbot Medical

    Microbot has completed multiple preclinical activities to provide preliminary safety and effectiveness information, and its approval by the FDA would allow the company to commence its pivotal human clinical trial in the United States.
    About Microbot Medical
    Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within the human body.
    The LIBERTY Endovascular Robotic Surgical System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The Company believes the LIBERTY Endovascular Robotic Surgical System’s remote operation has the potential to be the first system to democratize endovascular interventional procedures. Further information about Microbot Medical is available at http://www.microbotmedical.com.
    Home - Microbot Medical

    Home - Microbot Medical

    At Microbot, our innovative robotic technologies aim to allow accessibility for patients and other stakeholders. Our goal is to improve patients' lives by removing the barriers to optimal care, starting with the world's first single-use endovascular robotic system.

    Read More

    PRISM MarketView does not provide investment advice.
    Media Contact
    Company Name: Prism MarketView
    Email: info@prismmarketview.com
    Phone: 646-863-6341
    Website: https://prismmarketview.com
    To see this content properly accept cookies.
    PRISM MarketView Social Media
    To see this content properly accept cookies.
    To see this content properly accept cookies.
    Related Stories
    PRISM Daily
    PRISM MarketView Consumer Products Index Top Mover: Coty

    New York, February 21, 2024 - PRISM MarketView - Coty (NYSE: COTY), one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, and skin and body care, saw its stock up almost 4% after reiterating FY24 outlook of +9-11...

    21 February 2024

    PRISM Cannabis
    GrowGeneration Celebrates Drip Hydro’s Innovative Nutrient Line for Cannabis Cultivation

    New York, February 08, 2024 - PRISM MarketView - Drip Hydro has shaken up the cannabis cultivation industry with the introduction of its innovative powder nutrient line, designed specifically to optimize plant health and crop quality. This game-changing product marks a s...

    8 February 2024

    PRISM Biotech
    Cybin Reports Positive Topline Results in Depression Study

    New York, February 20, 2024 - PRISM MarketView - Cybin Inc. (NYSE American: CYBN) has reported its unaudited financial results for its third quarter ended December 31, 2023 and highlighted positive Phase 2 topline efficacy and safety data for CYB003, in the treatment of ...

    20 February 2024

    PRISM Biotech
    Intelligent Bio Solutions Surges Over 150% on Revenue Results

    New York, February 02, 2024 - PRISM MarketView - Shares in medical technology company Intelligent Bio Solutions (Nasdaq: INBS) soared by more than 150% on Friday after the company reported its (unaudited) revenue results for fiscal Q2 and the six months ended December 31...

    2 February 2024

    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.